Keytruda (pembrolizumab) received a supplemental approval from the U.S. Food and Drug Administration (FDA) on March 22, 2021. This approval, designated as an efficacy supplement (BLA 125514 S-96), indicates an expansion of the drug's approved uses based on new clinical data, with Merck Sharp Dohme as the sponsor.
Background
Pembrolizumab, marketed as Keytruda, is a well-established therapeutic agent sponsored by Merck Sharp Dohme. This supplemental approval represents an expansion of its approved applications, building upon its existing profile as an FDA-approved treatment.
What this means
A supplemental efficacy approval, such as the one granted to Keytruda (pembrolizumab) on March 22, 2021, signifies a significant regulatory milestone. It indicates that the U.S. Food and Drug Administration (FDA) has reviewed new clinical data and determined that the drug is effective for an additional use not covered by its previous approvals. This type of approval is distinct from an initial market authorization and typically expands the drug's label to include a new indication, a broader patient population for an existing indication, or a different treatment setting or line of therapy. The sponsor, Merck Sharp Dohme, would have submitted a supplemental Biologics License Application (sBLA) containing robust clinical trial evidence to support the efficacy and safety of pembrolizumab for this new application. For clinicians, these updates are crucial as they provide expanded therapeutic options, potentially allowing the drug to be used in patient groups who previously had limited treatment choices. Researchers gain insights into the drug's broader utility and potential new areas for investigation, while patient advocates can inform their communities about new approved treatment pathways. The FDA's decision reflects a thorough evaluation of the submitted data, confirming a positive benefit-risk profile for this expanded use of pembrolizumab.
Source
The U.S. Food and Drug Administration (FDA) granted this supplemental approval. The information is available on the accessdata.fda.gov website, referencing BLA 125514 S-96, dated March 22, 2021.